Laura E. Johnson, MD

Last month I reviewed key findings in HIV that were published within a 2-month interval near the end of 2007. I have extended that review here, reporting highlights of research announced in the last few weeks of 2007.

Almost 2 years ago I reviewed the topic of hepatitis C virus (HCV) infection in the setting of HIV.1 Given the advances–and some setbacks–in our understanding of HCV pathogenesis and treatment in the coinfected population, it's time for an update.

This year’s Conference on Retroviruses and Opportunistic Infections offered a symposium on “Driv­ers of the HIV Epidemic and Potential Interventions.”

In a midsummer issue of the Journal of Infectious Diseases, Dr Anthony Fauci1––who is as close as the United States comes to a tsar of AIDS medicine––describes 7 HIV-infected persons who had received protease inhibitor (PI)-based antiretroviral therapy for an average of 40.4 months (range, 31.1 to 54 months).